

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	出版年	巻号	ページ
Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, <u>Nakagawa K</u> , Terashima M, Okabe T, <u>Kaneda H</u> , McKee MD, Carlson DM, Xiong H, Tamura T.	A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).	Cancer Chemother Pharmacol	2014	74(1)	37-43
Kurata T, <u>Tsurutani J</u> , Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, <u>Nakagawa K</u> .	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer.	Invest New Drugs	2014	32(5)	946-954
Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N.	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	Lancet Oncol	2014	15(11)	1236-1244
Gemma A, Kudoh S, Ando M, Ohe Y, <u>Nakagawa K</u> , Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M.	Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.	Cancer Sci	2014	105(12)	1584-1590
Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, <u>Nishio K</u> , <u>Nakagawa K</u> .	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.	Oncotarget	2014	5(23)	11847-11856
Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, <u>Kaneda H</u> , Kurata T, <u>Tsurutani J</u> , Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, <u>Nakagawa K</u> .	Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer.	Thorac Oncol	2015	10(2)	346-352
Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, Iwamoto Y, Saka H, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, <u>Nakagawa K</u> , Saijo N, Tamura T.	Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L.	J Clin Oncol	2015	33(6)	575-581
Nishio M, Horiike A, Murakami H, Yamamoto N, <u>Kaneda H</u> , <u>Nakagawa K</u> , Horinouchi H, Nagashima M, Sekiguchi M, Tamura T.	Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.	Lung Cancer	2015	88(3)	275-281
Takeda M, Okamoto I, <u>Nakagawa K</u> .	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.	Lung Cancer	2015	88(1)	74-79
Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, <u>Nakagawa K</u> , <u>Nishio K</u> .	Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.	Lung Cancer	2015	88(1)	16-23